

## Orthocell Webinar Details – Remplir™ US FDA 510(k) Clearance

**Perth, Australia; 4 April 2025:** Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) will conduct a webinar today to discuss the US FDA 510(k) clearance for its flagship Remplir nerve repair product, the investor presentation has been separately announced to the ASX.

Orthocell’s Chairman, Mr John Van Der Wielen and CEO and Managing Director Mr Paul Anderson will provide an overview of this landmark announcement for the company.

Details of the webinar are as follows:

When: 11:00am EDST/8:00am AWST, Friday 4 April

Topic: Orthocell US FDA 510(k) Clearance for Remplir

Register in advance for this webinar:

[https://us02web.zoom.us/webinar/register/WN\\_wUB31EXVRpyqFTKu-fZM7A](https://us02web.zoom.us/webinar/register/WN_wUB31EXVRpyqFTKu-fZM7A)

After registering, you will receive a confirmation email containing information about joining the webinar.

**Release authorised by:**

Paul Anderson  
Orthocell Ltd CEO and MD

For more information, please contact:

**General & Investor enquiries**

**Paul Anderson**

**Orthocell Limited**  
**CEO and MD**

P: +61 8 9360 2888

E: [paulanderson@orthocell.com.au](mailto:paulanderson@orthocell.com.au)

**Media enquiries**

**Haley Chartres**

**HACK Director**

P: +61 423 139 163

E: [haley@hck.digital](mailto:haley@hck.digital)



## About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG), New Zealand (WAND), UK (UKCA Mark) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, is approved in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies Group. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit [www.orthocell.com](http://www.orthocell.com) or follow us on Twitter [@OrthocellLtd](https://twitter.com/OrthocellLtd) and LinkedIn [www.linkedin.com/company/orthocell-ltd](https://www.linkedin.com/company/orthocell-ltd)

## Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

